Empagliflozin protects the kidney by reducing toxic ALB (albumin) exposure and preventing autophagic stagnation in proximal tubules.

• Tác giả: Yoshitaka Isaka, Shihomi Maeda, Jun Matsuda, Isao Matsui, Sho Matsui, Ayumi Matsumoto, Satoshi Minami, Jun Nakamura, Tomoko Namba-Hamano, Shinsuke Sakai, Yoshitsugu Takabatake, Atsushi Takahashi, Takeshi Yamamoto, Motoko Yanagita, Hiroaki Yonishi
• Ngôn ngữ: eng
• Thông tin xuất bản: United States : Autophagy , 2025
• Bộ sưu tập: NCBI
• ID: 215469

Tóm tắt

The renoprotective effects of SLC5A2/SGLT2 (solute carrier 5 (sodium/glucose cotransporter), member 2) inhibitors have recently been demonstrated in non-diabetic chronic kidney disease (CKD), even without overt albuminuria. However, the mechanism underlying this renoprotection is largely unclear. We investigated the renoprotective mechanisms of the SLC5A2 inhibitor empagliflozin with a focus on ALB (albumin) reabsorption and macroautophagy/autophagy in proximal tubules using wild-type or drug-inducible